Printer Friendly

AMERICAN BIOGENETIC SCIENCES FIBRINOGEN ANTIBODY PATENT NO. 5,091,512 ISSUED

 AMERICAN BIOGENETIC SCIENCES FIBRINOGEN ANTIBODY
 PATENT NO. 5,091,512 ISSUED
 NOTRE DAME, Ind., Feb. 25 /PRNewswire/ -- American Biogenetic Sciences, Inc. (NASDAQ: MABXA) (ABS) announced today that it has received United States Patent No. 5,091,512 covering its monoclonal antibody 45-J.
 The 45-J monoclonal antibody is utilized in the company's first commercial product, "Cadkit," a manual test that measures levels of fibrinogen in blood plasma. Fibrinogen is gaining increasing recognition as a major independent risk factor for cardiovascular disease. Several population-based studies have found that elevated levels of fibrinogen eclipse cholesterol as a predictor of future cardiovascular events such as heart attacks.
 ABS recently entered into an exclusive 15-year license agreement with Yamanouchi Pharmaceutical Co., Ltd. For Yamanouchi to market assays containing ABS's monclonal antibody, 45-J, in Japan and Taiwan. Under terms of the agreement, Yamanouchi made an initial cash payment to ABS and ABS will receive royalty payments equal to 10 percent on all sales of the assays which contain antibody 45-J.
 Based on 100 million cholesterol tests administered annually in the United States, ABS President, Henry L. Nordhoff, estimates the potential worldwide annual market for a fibrinogen test at about $400 million. The market potential is expected to include its use during routine physical examinations in men over 35 and in post-menopausal women. Use of the test to monitor fibrinogen levels during clot dissolving therapy is also being investigated.
 The Cadkit, which received U.S. Food and Drug Administration clearance of a 510(k) application in 1991, is a manual latex agglutination test that directly measures fibrinogen levels by utilizing the 45-J monoclonal antibody, which is highly specific for fibrinogen. The Cadkit is being test marketed in Europe. ABS is discussing U.S. marketing rights to an automated version of Cadkit with a number of major pharmaceutical companies.
 American Biogenetic Sciences, Inc. is a biopharmaceutical company which conducts research at the University of Notre Dame and Trinity College, Dublin, Ireland, to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease and for diagnosing Alzheimer's disease. These antibodies are produced from the company's proprietary germ-free and antigen-minimized mouse colony. The company is also developing a recombinant vaccine for Hepatitis A.
 -0- 2/25/92
 /CONTACT: Fran Giambanco, vice president-administration of American Biogenetic Sciences, 516-789-2600, or Bonnie Sterling of Noonan/Russo Communications, 212-979-9180, for American Biogenetic Sciences/
 (MABXA) CO: American Biogenetic Sciences, Inc. ST: Indiana IN: MTC SU: PDT


PS -- NY005 -- 2197 02/25/92 09:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1992
Words:413
Previous Article:ORTHOMET ANNOUNCES AGREEMENT TO ACQUIRE ENDOTEC
Next Article:CORNING ANNOUNCES MAJOR ADVANCE IN REDUCING AUTOMOBILE POLLUTION
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES, FIBRINOGEN ANTIBODY PATENT ALLOWED
AMERICAN BIOGENETIC SCIENCES RECEIVES $10.3 MILLION IN WARRANT EXERCISE
AMERICAN BIOGENETIC SCIENCES SIGNS LICENSE AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
AMERICAN BIOGENETIC SCIENCES RECEIVES $15.5 MILLION FROM 100 PERCENT EXERCISE OF WARRANTS
AMERICAN BIOGENETIC SCIENCES CEO SENDS UPDATE LETTER TO SHAREHOLDERS
AMERICAN BIOGENETIC SCIENCES SENDS LETTER TO SHAREHOLDERS
American Biogenetic obtains patent for the treatment of malignant and benign tumors.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters